Kiora Pharmaceuticals Reports its Ion Channel Modulator, KIO-300, Suppressed Seizure Activity in Preclinical Epilepsy Model
Encinitas, California--(Newsfile Corp. - June 18, 2026) - Kiora Pharmaceuticals (NASDAQ: KPRX) today announced preclinical data showing that KIO-300, part of the company's novel ion channel modulator platform, significantly suppressed seizure-associated electrophysiological activity in an ex vivo temporal lobe epilepsy (TLE) model. The findings were presented in a poster at the Epilepsy Foundation Pipeline Conference taking place June 18-19, 2026, in Leesburg, VA. "These data reinforce
Biotechnologies, Pharmaceutique
2026-06-18 7:00 AM EDT | Kiora Pharmaceuticals, Inc.
Restart Life Advances AI-Driven E-Commerce Strategy to Scale Online Sales Growth for Holy Crap Foods
Vancouver, British Columbia--(Newsfile Corp. - June 18, 2026) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to announce that its wholly owned subsidiary, Holy Crap Foods Inc., is preparing to begin harnessing predictive AI to further its e-commerce consumer and wholesale sales platform. The initiative is engineered to leverage readily available predictive consumer behavior models to optimize, monetize, and scale the brand'
Technologies, Biotechnologies, Santé
2026-06-18 6:00 AM EDT | Restart Life Sciences Corp.
MustGrow Increases Non-Brokered LIFE Offering to Approximately $3.7 Million
Saskatoon, Saskatchewan--(Newsfile Corp. - June 17, 2026) - MustGrow Biologics Corp. (TSXV: MGRO) (OTC: MGROF) (FSE: 0C0) (the "Company" or "MustGrow"), is pleased to announce that, in connection with its previously announced non-brokered private placement of units (each, a "Unit") at a price of $0.50 per Unit, and as a res
Agriculture, Biotechnologies, Cannabis, Sélectionneurs de cannabis
2026-06-17 7:21 PM EDT | MustGrow Biologics Corp.
Hemostemix' $1,000,000 Private Placement and Update
Calgary, Alberta--(Newsfile Corp. - June 17, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce that the Company is closing up to $1,000,000 of financing in tranches from the sale of Units at $0.05 each. Each Unit shall consist of one Common Share in the capital of the Company ("Common Share") and one half common share purchase warrant ("1/2 Warrant"), with each whole Warrant (2 x 1/2 Warrants) entitling the holder to acquire one Common Share at a price of $
Biotechnologies, Pharmaceutique, Santé
2026-06-17 5:22 PM EDT | Hemostemix Inc.
Defence Therapeutics to Participate in Bio International Convention 2026 Next Week for Strategic Partnership Discussions
Montreal, Quebec--(Newsfile Corp. - June 17, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to announce its participation in the BIO International Convention 2026, taking place June 22-25 in San Diego, California. Defence's team will be available throughout the conference to meet with pharmaceutical and biotechnology companies, investors, an
Biotechnologies, Pharmaceutique, Santé
2026-06-17 3:15 AM EDT | Defence Therapeutics Inc.
Medexus Schedules Fourth Fiscal Quarter and Fiscal Year 2026 Conference Call
Ontario and Chicago, Illinois--(Newsfile Corp. - June 16, 2026) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Friday, June 26, 2026 to discuss Medexus's results for its fourth fiscal quarter and fiscal year ended March 31, 2026. Medexus expects to file its financial statements and MD&A after markets close on June 25, 2026. To participate in the call, please dial the following numbers:
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-06-16 5:30 PM EDT | Medexus Pharmaceuticals Inc.
CBIH Announces Patent-Related Scientific Framework for PTSD-Focused Cannabinoid and Psilocybin Research
Houston, Texas--(Newsfile Corp. - June 15, 2026) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company trading under the ticker symbol CBIH, today announced a new chapter in its PTSD-focused research journey, marked by the completion of its patent-related work and the continued exploration of the scientific relationship between cannabinoids and psilocybin in relation to trauma, memory, emotional regulation, and recovery. PTSD affects veterans, first responde
Biotechnologies, Pharmaceutique, Cannabis, Santé
2026-06-15 7:00 AM EDT | Cannabis Bioscience International Holdings
PreveCeutical Closes Second Tranche of Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - June 12, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical"), is pleased to announce that, further to its news releases dated May 12, 2026 and April 22, 2026, it has closed a second tranche (the "Second Tranche") of its previously announced non-brokered private placement (the "Offering"), which Second Tranche consisted of the issuance of 9,800,000 units
Biotechnologies, Pharmaceutique, Santé
2026-06-12 5:39 PM EDT | PreveCeutical Medical Inc.
Bachem Holding AG Announces Capital Markets Day 2026
Bubendorf, Switzerland--(Newsfile Corp. - June 12, 2026) - Bachem Holding AG (SIX: BANB) will host its Capital Markets Day on 26 November 2026 at The Circle Convention Center, Hyatt Regency Zurich Airport, as well as virtually. This hybrid event will provide insights into the company's strategic priorities, business outlook, and key developments.
Biotechnologies, Produits chimiques, Soins de santé et hôpitaux, Pharmaceutique
2026-06-12 11:47 AM EDT | Bachem Holding AG
Neural Therapeutics Announces AGSM Results, CFO Appointment and Welcomes Positive Developments in the German Cannabis Market
Toronto, Ontario--(Newsfile Corp. - June 12, 2026) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company") is pleased to announce the results of its annual general and special meeting of shareholders held on May 25, 2026 (the "Meeting"), including shareholder approval of the acquisition by Neural of the remaining 69.25% equity interest in CWE European Holdings Inc. ("CWE") not already owned by the Company, through a series of ancillary transa
Biotechnologies, Pharmaceutique, Santé, Psychédéliques
2026-06-12 7:30 AM EDT | Neural Therapeutics Inc.
Britannia Life Sciences Announces $5.3 Million Acquisition of Commercial Equipment Loan Portfolio
Toronto, Ontario--(Newsfile Corp. - June 12, 2026) - Britannia Life Sciences Inc. (CSE: BLAB) (the "Company" or "Britannia") is pleased to announce that it has completed a strategic investment of approximately $5.3 million in a portfolio of performing commercial equipment loans (the "Investment") on highly opportunistic terms. The Investment represents the continued execution of the Company's asset-backed lending strategy and meaningfully expands the Company's base of recurring, high-return c
Biotechnologies, Produits ménagers / de consommation / cosmétiques, Santé, Fournisseurs de services auxiliaires liés au cannabis
2026-06-12 7:30 AM EDT | Britannia Life Sciences Inc
Restart Life Subsidiary Holy Crap Foods Marks New International Expansion Milestone with Bahamas On-Demand App Launch
Vancouver, British Columbia--(Newsfile Corp. - June 10, 2026) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to announce that its wholly owned subsidiary, Holy Crap Foods Inc., has officially launched a targeted market test and comprehensive product trial across the Commonwealth of The Bahamas. The pilot program is being executed in direct partnership with a premier mobile-first delivery application, digital logistics, and
Technologies, Biotechnologies, Santé
2026-06-10 8:00 AM EDT | Restart Life Sciences Corp.
CORRECTION FROM SOURCE: Entheon Biomedical Corp. Issues Correction to News Release Dated June 9, 2026
Vancouver, British Columbia--(Newsfile Corp. - June 9, 2026) - Entheon Biomedical Corp. (CSE: ENBI.X) (OTCID: ENTBF) (FSE: 1XU) ("Entheon" or the "Company") wishes to correct the effective date of the appointment of Adam Emes as a director of the Company as stated in the Company's news release dated June 9, 2026. The appointment of Mr. Emes to the Company's Board of Directors is effective June 9, 2026, not April 3, 2025 as previously stated. All other information contained in th
Biotechnologies, Cannabis, Psychédéliques, Fournisseurs de services auxiliaires liés au cannabis
2026-06-09 7:32 PM EDT | Entheon Biomedical Corp.
Medexus Announces License and Supply Deal for UM171 Cell Therapy in Canada
Ontario and Chicago, Illinois--(Newsfile Corp. - June 9, 2026) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF)
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-06-09 5:30 PM EDT | Medexus Pharmaceuticals Inc.
Entheon Announces Change of Directors
Vancouver, British Columbia--(Newsfile Corp. - June 9, 2026) - Entheon Biomedical Corp. (CSE: ENBI.X) (OTCID: ENTBF) (FSE: 1XU) ("Entheon" or the "Company") announces the appointment of Adam Emes to the Company's Board of Directors, effective April 3, 2025. Mr. Emes is a seasoned entrepreneur with extensive experience in capital markets, corporate development and investor relations. He is the Co-Founder of Black Swan Solutions Inc., where he has worked with over 80 clients
Biotechnologies, Cannabis, Psychédéliques, Fournisseurs de services auxiliaires liés au cannabis
2026-06-09 4:26 PM EDT | Entheon Biomedical Corp.
BioMark Secures Broad U.S. Patent for Urine-Based Lung Cancer Screening, Expanding Differentiated Liquid Biopsy Testing Platform
Vancouver, British Columbia--(Newsfile Corp. - June 9, 2026) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark" or the "Company"), a leading developer of liquid biopsy technologies for early cancer detection, is pleased to announce that the United States Patent and Trademark Office (USPTO) has issued a Notice of Patent Allowance for Application No. 18/304,741, titled "Method of Detecting Lung Cancer." The allowed patent covers the proprietary use of ur
Technologies, Biotechnologies, Soins de santé et hôpitaux
2026-06-09 8:30 AM EDT | BioMark Diagnostics, Inc.
Dr. Christina Rahm and The ROOT Brands Celebrate Dual Gold Stevie(R) Awards in New York City
New York, New York--(Newsfile Corp. - June 8, 2026) - Dr. Christina Rahm and The ROOT Brands are celebrating a milestone moment as company leadership gathers in New York City for the 24th Annual American Business Awards®, where both the organization and its founder, Dr. Christina Rahm, have been recognized with prestigious Gold Stevie® Awards for innovation, manufacturing excellence and scientific leadership. The national recognition highlights the contin
Biotechnologies, Aliments / boissons, Santé
2026-06-08 5:57 PM EDT | DRC Ventures
Lifordi Immunotherapeutics Presents Phase 1 Clinical Data for LFD-200, a Subcutaneous Glucocorticoid Antibody Drug Conjugate, at EULAR 2026
Burlington, Massachusetts--(Newsfile Corp. - June 8, 2026) - Lifordi Immunotherapeutics, Inc., a clinical-stage biotechnology company developing antibody-drug conjugates (ADCs) for the treatment of autoimmune and inflammatory disorders, presented first-in-human data for LFD-200, the Company's novel subcutaneously (SC) administered ADC delivering a potent glucocorticoid (GC) directly to immune cells. Phase 1 data from healthy participants (HPs) presented at EULAR 2026 (European
2026-06-08 8:31 AM EDT | Lifordi
CBIH Advances Strategic Pathway to Bring VitaCookies' Science-Driven Functional Wellness Platform to Texas Consumers
Houston, Texas--(Newsfile Corp. - June 8, 2026) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public biotechnology company trading under the ticker symbol CBIH, today announced that it has completed and submitted the required documentation as part of its Texas licensing process related to the planned commercialization of VitaCookies, its cannabinoid-formulated functional wellness cookie line. CBIH intends to move forward carefully, with a focus on licensing and franchisi
Biotechnologies, Pharmaceutique, Cannabis, Santé
2026-06-08 7:00 AM EDT | Cannabis Bioscience International Holdings
OS Therapies Achieves Global Regulatory Alignment on Design of Phase 3 Trial of OST-HER2 in Fully Resected, Pulmonary Metastatic Osteosarcoma
Confirmatory Phase 3 trial to commence prior to BLA grant under Accelerated Approval Program in the U.S. and Conditional MAA in the U.K., Europe and Australia Patent pending pharmacodynamic response biomarker accepted as surrogate clinical efficacy endpoint TGA and MHRA agree to allow utilization of remaining Phase 2b drug product for initiation of confirmatory Phase 3 FDA and EMA fully align with Company on Chemistry, Manufacturing and Con
2026-06-08 6:00 AM EDT | OS Therapies